drugset / Trial / NCT00700193
A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to determine the Safety, Tolerability \& Immunogenicity of CSL Limited's Influenza Virus Vaccine in a two dose primary vaccination series, with a 12-month booster vaccination, in a paediatric population equal to or greater than 6 months to less than 9 years old.
Timeline
- Start
- 2005-03
- Primary completion
- 2006-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Influenza Virus Vaccine | Vaccine | 0.25 ml | — |
| Subject | Influenza Virus Vaccine | Vaccine | 0.5 ml | — |